JP2024125140A5 - - Google Patents
Info
- Publication number
- JP2024125140A5 JP2024125140A5 JP2023083815A JP2023083815A JP2024125140A5 JP 2024125140 A5 JP2024125140 A5 JP 2024125140A5 JP 2023083815 A JP2023083815 A JP 2023083815A JP 2023083815 A JP2023083815 A JP 2023083815A JP 2024125140 A5 JP2024125140 A5 JP 2024125140A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- pharmaceutical composition
- chemotherapeutic agent
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310201602.2 | 2023-03-03 | ||
| CN202310201602.2A CN116407640B (zh) | 2023-03-03 | 2023-03-03 | 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024125140A JP2024125140A (ja) | 2024-09-13 |
| JP2024125140A5 true JP2024125140A5 (https=) | 2026-04-20 |
Family
ID=86497784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083815A Pending JP2024125140A (ja) | 2023-03-03 | 2023-05-22 | アズブジンと化学療法剤とを含む抗腫瘍医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12268702B2 (https=) |
| EP (1) | EP4424316B1 (https=) |
| JP (1) | JP2024125140A (https=) |
| KR (1) | KR20250167640A (https=) |
| CN (1) | CN116407640B (https=) |
| TW (1) | TW202435896A (https=) |
| WO (1) | WO2024183645A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116407640B (zh) * | 2023-03-03 | 2025-10-31 | 河南真实生物科技有限公司 | 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 |
| CN116196325A (zh) * | 2023-03-10 | 2023-06-02 | 河南真实生物科技有限公司 | 包含阿兹夫定的免疫调节剂组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2201296T3 (es) * | 1996-04-26 | 2004-03-16 | Genaera Corporation | Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores. |
| CN102000103B (zh) * | 2009-12-21 | 2011-12-21 | 郑州大学 | 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用 |
| CA2873112A1 (en) * | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| JP6878417B2 (ja) * | 2016-02-17 | 2021-05-26 | トリアステック インコーポレイテッド | 剤形およびそれらの使用 |
| EP3508205B1 (en) * | 2016-08-31 | 2022-05-18 | FUJIFILM Corporation | Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit |
| WO2020001475A1 (en) * | 2018-06-29 | 2020-01-02 | Shanghai Changchengyiyaokeji Company Limited | Phosphorus-containing prodrugs of gemcitabine |
| WO2020142629A1 (en) * | 2019-01-02 | 2020-07-09 | The General Hospital Corporation | Reverse transcriptase blocking agents and methods of using the same |
| WO2021209740A1 (en) * | 2020-04-16 | 2021-10-21 | Mereo Biopharma 4 Limited | Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection |
| US20230218644A1 (en) * | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| TW202228724A (zh) * | 2020-09-23 | 2022-08-01 | 美商昂克萊亞製藥公司 | 以反轉錄酶抑制劑治療癌症之方法 |
| CN116407640B (zh) * | 2023-03-03 | 2025-10-31 | 河南真实生物科技有限公司 | 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 |
-
2023
- 2023-03-03 CN CN202310201602.2A patent/CN116407640B/zh active Active
- 2023-05-22 US US18/200,000 patent/US12268702B2/en active Active
- 2023-05-22 EP EP23174495.4A patent/EP4424316B1/en active Active
- 2023-05-22 JP JP2023083815A patent/JP2024125140A/ja active Pending
-
2024
- 2024-03-01 KR KR1020257033468A patent/KR20250167640A/ko active Pending
- 2024-03-01 WO PCT/CN2024/079626 patent/WO2024183645A1/zh not_active Ceased
- 2024-03-01 TW TW113107343A patent/TW202435896A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024125140A5 (https=) | ||
| JP2021120406A5 (ja) | 癌を治療するための組み合わせ物 | |
| JP2012153722A5 (https=) | ||
| KR101230085B1 (ko) | ７―(２,５-디히드로―４-이미다조［１,２-ａ］피리딘-３-일-２,５-디옥소-１ｈ-피롤-３-일)-９-플루오로-１,２,３,４-테트라히드로-２-(１-피페리디닐카르보닐)-피롤로［３,２,１-ｊｋ］［１,４］벤조디아제핀에 의한 암 화학요법의 강화 | |
| JP2019535746A5 (https=) | ||
| JP2020531447A5 (https=) | ||
| RU2016130986A (ru) | Ингибитор киназы и его применение | |
| RU2008117295A (ru) | Новые пиразолопиримидины как ингибиторы циклинзависимых киназ | |
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| JP2010270124A5 (https=) | ||
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| IL319292A (en) | Cytotoxic imidazo[2,1-A]pyridine compounds and their use in therapy | |
| JP2014534269A5 (https=) | ||
| JP2024125139A5 (https=) | ||
| WO2013170637A1 (zh) | 芍药苷类化合物在制备抗肿瘤药物中的用途 | |
| JPWO2020032105A5 (https=) | ||
| JP2023088996A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| CN105209032A (zh) | 使用转录因子调节剂治疗癌症和其他病症 | |
| TWI615145B (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JPWO2022074617A5 (https=) | ||
| CN104971361A (zh) | 一种叶酸受体靶向的敲除dnmt1基因的药物组合物 | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| JP2010509306A5 (https=) | ||
| JPWO2021005183A5 (https=) |